

Cover Story
Free
By Matthew Bin Han Ong
The proportion of racial and ethnic minority patients in NCI-funded clinical trials has nearly doubled over two decades—from 14% in 1999 to 25% in 2019, according to data from NCI's National Clinical Trials Network and the NCI Community Oncology Research Program.
In Brief
Clinical Roundup


Drugs & Targets


Trending Stories
- Elisa Rodriguez named first chief diversity and equity officer for faculty at Roswell Park
- Nancy Goodman: “Sen. Sanders says he cares about kids with cancer. I’m just asking him to show us.”
- Gregory Curt, Clinician and Drug Developer, Dies at 64
- Mikaela Naylon Give Kids a Chance Act nixed by Senate
- Otis Brawley looks back on a year of great science and greater challenges
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
















